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Immune status of RB51 vaccinated buffaloes was evaluated using tube agglutination test (TAT) and 
ELISA, using both periplasmic protein antigen (PPA) and lipopolysaccharide antigen (LPS). For this 
purpose, three groups of buffalo calves were used. The first one received S19 vaccine subcutaneously; 
the second was vaccinated once subcutaneously with RB51 vaccine. The third (control) group was 
injected similarly with sterile saline. Concerning the S19 vaccinated group, significant TAT titers were 
seen 1 week post vaccination (WPV) till the maximum at the 2
nd
 WPV. After that it was gradually 
decreased till the 7 WPV, then sharply before it completely disappeared at the 13 WPV. On the other 
hand, the LPS-ELISA showed an antibody titer as early as one WPV reached its peak at 2 WPV and 
persisted steadily till the 6
th
 WPV and decreased slowly when it reached minimal level at the 16 WPV till 
the end of the experiment. While in RB51 vaccinated buffalo calves using the PPA-ELISA, the antibody 
titer began and reach the maximum as early as the first WPV, still steady till 2 WPV, fluctuating till the 
6th WPV, then dropped sharply when it disappeared at 11WPV till the end of the experiment. 
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Bovine brucellosis is one of the most important zoonotic 
diseases worldwide, especially in developing countries 
and is responsible for serious economic losses due to 
late term abortion, stillborn and weakly calves (Neta et 
al., 2010). The occurrence of the disease in humans is 
largely dependent on the animal reservoir (Adone et al., 
2005). Brucella control programs mainly depend on 
vaccination, mostly with attenuated Brucella abortus 
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Abbreviations: TAT, Tube agglutination test; WPV, week post 
vaccination; BAPAT, buffered acidified plate agglutination test; 
RBPT, Rose Bengal plate test; LPS, lipopolysaccharide; PPA, 
periplasmic proteins antigen; pv, post vaccination. 
B. abortus and prevents premature abortions in cattle 
(Nicoletti, 1990) and buffalo worldwide (OIE, 2009). 
However, this vaccine has the drawback of inducing O-
polysaccharide-specific antibodies that interfere with the 
discrimination between vaccinated and infected animals 
during serological screening (Salmakov et al., 2010). In 
addition, they retain pathogenicity and sometimes cause 
abortion in vaccinated animals (Diptee et al., 2006) and 
cause the disease in humans. 
To overcome the problem of serological interference, 
RB51, a mutant vaccinal rough strain that is devoid of the 
LPS O-side chain was developed (Poester et al., 2006). 
Consequently, cattle vaccinated with RB51 do not sero-
convert on conventional brucellosis serologic tests 
(Robles et al., 2009). Therefore, this vaccine is more 
appropriate than B. abortus S19 for control and eradica-
tion programs that rely on serologic testing and removal 
of positive animals. 






cattle under experimental (Olsen, 2000) and field 
conditions (Lord et al., 1998); although, there are few 
reports about abortion induced by RB51 vaccine (Yazdi 
et al., 2009) and shedding of the micro-organism in 
buffaloes milk (longo et al., 2009). Most studies in cattle 
reported that RB51 provides protection against moderate 
challenge (Martins et al., 2009), but less effective than 
S19 against severe challenges (Moriyon et al., 2004). 
Moreover, elk (Cervus elaphus) vaccinated with RB51 
are not protected from infection and abortion (Kreeger et 
al., 2002). Fosgate et al. (2003), further demonstrated 
that the RB51 vaccine, administered at the recommended 
calfhood dose, failed to protect water buffalo from 
infection following natural exposure to B. abortus biovar 
1. To our knowledge, official use of RB51 in domestic 
water buffalo has not been reported.Therefore, the aim of 
this study was to provide a simple and effective method 
for the identification of RB51 vaccinated buffalo and 
overcome illegal vaccination beside the evaluation of the 
RB51 vaccine efficacy in the vaccination campaigns. 
 
 
MATERIALS AND METHODS 
 
B. abortus RB51 vaccine (Professional Biological Company, 4950 
York Street, Denver, CO) and B. abortus S19 were kindly provided 
by Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt. 
Viable counts were performed at the time of inoculation. 
30 Egyptian female buffalo calves, 6 months old were obtained 
from a ‘‘brucellosis-free’’ farm during 2007 to 2008. Animals had  
received routine preventive medicine including vaccinations and 
dewormings and appeared to be in good general health when 
examined. No animal had a history of acute or chronic illnesses. All 
animals were tested negative for brucellosis on buffered acidified 
plate agglutination test (BAPAT) and Rose Bengal plate test 
(RBPT) as described earlier (Alton et al., 1988). These buffalo 
calves were divided into three groups each, of ten animals: Group 1 
received 1 to 2 x 10
10
 CFU of S19 vaccines subcutaneously as 
described earlier (Uzal et al., 2000). Group 2 was vaccinated once 
with (1.0 to 3.4) × 10
10 
CFU of RB51 vaccine subcutaneously in the 
left prescapular region according to manufacturer’s 
recommendations for calfhood vaccination of cattle (Stevens et al., 
1997). Animals in the non-vaccinated control group (Group 3) were 
injected similarly with 2 ml sterile saline solution. Blood was 
obtained by jugular venipuncture before and at zero week post 
vaccination (WPV) and weekly till 20 WPV. Sera were separated 
and stored at 4°C till used. All stages were conducted with 
consideration of their welfare and all procedures with animals were 
carried out in accordance with appropriate humane methods. 
All the work was done in the National Research Center (NRC), 
Animal Reproduction Research Institute (ARRI) and the Central 
Laboratory for Evaluation of Veterinary Biologics (CLEVB). 
 
 
Serological testing and antigens 
 
All animals were tested for anti-B. abortus and anti-RB51 antibodies 
before vaccination, on the day of vaccination (day zero) and then 
periodically until 20 weeks post vaccination (WPV). Anti- B. abortus 
antibodies were verified using both tube agglutination test (TAT) 
according to Alton et al. (1988) and ELISA using B. abortus M-99 
crude lipopolysaccharide (LPS-ELISA) according to Plackett et al. 
using the B. abortus M-99 periplasmic proteins (PPA-ELISA)  




(1976). While Anti-RB51 antibodies were monitored with ELISA 
prepared according to Yifan et al. (1993). 
 
 
Extraction of B. abortus periplasmic protein antigen (PPA)  
 
B. abortus M-99 was cultured on the growth medium for 3 to 4 days 
at 37°C in CO2 incubator. After the growth of the organism, they 
were harvested, and then washed 3 times using 0.15 M sodium 
chloride by centrifugation at 3000 rpm/15 min, pellet was re-
suspended using the same buffer, 0.15 M sodium chloride and then 
autoclaved at 120°C/20 min (hot saline extract method). The 
suspension of the autoclaved organism was centrifuged at 12,000 
rpm for 30 min, then the supernatant was separated and 
ammonium sulphate was added. The precipitated proteins were 
collected by centrifugation at 3000 rpm/15 min, then the pellets 
were resuspended in 0.01 M phosphate buffer saline (PBS). 
Dialysis occurred against PBS in dialysis bag overnight at 4°C; 
aspiration of the solution occurred and was lifted at -20°C till used. 
 
 
ELISA assay  
 
ELISA assay on serum samples was performed as mentioned 
earlier (Bassiri et al., 1993) using both periplasmic and LPS 





Sera from all buffaloes calves (RB51-vaccinated and 
control) gave negative results to TAT and ELISA using 
Brucella crude LPS prior to vaccination, on day zero and 
during the entire study. All animals were also negative to 
PPA-ELISA prior to vaccination and on day zero, while 
after vaccination, vaccinated animals developed a 
serological response to RB51. 
Significant TAT titers in S19 vaccinated buffaloes 
(Figure 1) were seen as early as 1 WPV, while  the  
highest  TAT titer was observed at the 2WPV, then 
gradually declined till 7 WPV, and sharply when all 
animals became sero-negative at 13WPV. 
Concerning LPS-ELISA in S19 vaccinated buffaloes 
(Figure 2), antibody titer began as early as 1 WPV, 
reached its peak at 2 WPV and persisted steadily till the 
6
th
 WPV, then decreased slowly till it reached minimal 
level at the 16 WPV till the end of the experiment. By 
using periplasmic protein antigen (PPA) (Figure 3), the 
average PPA-ELISA titer in buffalo calves vaccinated 
with RB51 reached the maximum as early as 1 WPV, still 
steady till 2 WPV and fluctuated till the 6 WPV, then 
dropped sharply when it disappeared at the 11 WPV up 
to the end of the experiment. Control animals (Group 3) 
maintained their negative serological status during the 
complete experimental period. 
The RB51 vaccination did not interfere with the 
conventional diagnostic serology tests like TAT and 
ELISA using the LPS as antigen. The PPA-ELISA was 
able to detect antibodies produced by the RB51 
vaccination in buffaloes. 
 






Figure 1. TAT serologic responses in buffaloes vaccinated with B. abortus S19 vaccine. 
TAT investigated for 20 weeks post vaccination; serum was obtained before (time 0) and 







Figure 2. LPS-ELISA serologic responses (as O.D.) in buffaloes vaccinated with B. 








Figure 3. PPA-ELISA serologic responses (as O.D.) in buffaloes vaccinated with 








Brucellosis is a disease of socio-economic and public 
health importance
 
and has significant impact on the 
international trade of animals and animal products (OIE, 
2004) as it causes abortions and reduced fertility in cattle 
and water buffalo (Mohan, 1968). 
The water buffalo is potentially the most important 
tropical bovine species in areas where rivers and 
swamps abound (Shaffie, 1985), yet there is no reported 
effective vaccine against brucellosis in this valuable 
livestock species (Fosgate et al., 2003). 
Recent reports (Fosgate et al., 2002) showed 
differences in sensitivities and specificities of brucellosis 
serological tests between cattle and buffalo. Furthermore, 
Fosgate et al. (2003) showed that the B. abortus RB51 
administered at the recommended calfhood dose failed to 
protect water buffalo from infection following natural 
exposure to B. abortus biovar 1. Moreover, Kreeger et al. 
(2002) demonstrated that elk (C. elaphus) vaccinated 
with RB51 were not protected from infection and abortion. 
The poor cell-mediated immune response may be the 
reason for this vaccine inefficacy as reported by Olsen 
(2000). 
As a new approach to elevate the efficiency of RB51 
vaccine in buffalo, some authors have suggested the 
possibility of using a vaccination scheme that differs from 
that used in cattle (Iovan et al., 2007; Caporale et al., 
2010), such as vaccination of impuberal buffalo with a 
triple dose than that used in cattle and a booster dose 
after one month. This proved safe in young animals but 
caused abortions in vaccinated pregnant female buffalo 
(Galiero, 2009). Others suggested that RB51 vaccine 
alone does  not  eliminate  the  problem  of  brucellosis  in  
endemic zones and it is necessity to apply strict bio-
security measurements, such as removing seropositive 
animals (Herrera-LÓpeza et al., 2010). 
Recently, with the gradual use of RB51 vaccine, it 
became necessary to develop a method capable of 
identifying animals vaccinated with RB51 vaccine (Robles 
et al., 2003).
 
This include a dot-blot assay using killed 
irradiated RB51 bacteria as an antigen (Olsen et al., 
1997), iELISAs using a 5% optical density heat-killed 
whole RB51 organisms as an antigen (Edmonds et al., 
1999), and a crude rough LPS preparation from RB51 
(Uzal et al., 2000), Dot-Blot ELISA (Fosgate et al., 2003; 
Diptee et al., 2007), an immunoblot analysis using 
sonicated cell lysates from RB51 (Edmonds et  al., 1999), 
a complement fixation test, using RB51 cultured cells in 
calcium–magnesium-veronal buffer (Diptee et al., 2007; 
Galiero, 2009; Caporale et al., 2010) and an agar gel 
immunodifusion test using hot saline extract antigen from 
Brucella ovis (Robles et al., 2009). Unfortunately all these 
methods were unpractical and time consuming. 
According to results in Figure 1, significant TAT titers in 
S19 vaccinated buffalo were seen as early as 1 WPV, 
while the highest TAT titer was observed at 2 WPV, it  




declined gradually till 7 WPV, then sharply when all 
animals became sero-negative at 13 WPV. 
In comparison with the S19 vaccination in buffalo, 
Jamal et al. (2003) reported that using TAT, the anti-
bodies declining rate was slow from day 14 to 49 post-
vaccination, after that a rapid decrease was seen till the 
91
th
 day post vaccination and negligible after that. 
Concerning LPS-ELISA in S19 vaccinated buffaloes, it 
showed an antibody titer (Figure 2) as early as 1 WPV, 
reached its peak at 2 WPV and persisted steadily till the 
6
th
 WPV, and then decreased slowly till it reached mini-
mal level at the 16 WPV till the end of the experi-ment, 
while using PPA, the average PPA-ELISA titer in buffalo 
calves vaccinated with RB51 shown in Figure 3 began 
and reached the maximum as early as 1 WPV, still 
steady till 2 WPV and fluctuated till the 6 WPV, and then 
dropped sharply till it disappeared at the 11 WPV up to 
the end of the experiment. 
This was significably different from the results of RB51 
vaccination in cattle calves as reported by Tittarelli et al. 
(2008) which showed an immune response that began 
with an increase at day 6 post-vaccination, the antibody 
level remained constant for two months, then progress-
sively decreased. All vaccinated animals remained 
negative from day 162 post vaccination (pv) to the end of 
the study (day 300 pv). 
This means that the antibody titer persisted for 
significantly shorter period than that of S19, and since 
antibodies developed against RB51 may have limited 
abilities to opsonize smooth Brucella strains, therefore, 
the failure of RB51 vaccination to induce comparable 
protection to S19 vaccination may be due to antibodies 
induced by RB51 which failed to bind and opsonize 
smooth strains of Brucella (Fosgate et al., 2003; Olsen et  
al., 2006). So, in brucellosis endemic zones, vaccination 
with RB51 alone is not enough to control disease. It is 
necessary to eliminate all positive animals at the time of 
vaccination and all new positive animals after that for 
long periods of time (Herrera-L peza et al., 2010). 
The results of this study confirm the possibility of using 
PPA-ELISA to identify RB51 vaccinated buffalo and 
moreover, monitor antibody responses to RB51 
vaccination up to 11 WPV. Besides, negative results to 
TAT and LPS-ELISA confirm the impossibility to detect 
specific RB51 antibodies with the conventional 
serological tests which is in agreement with that of others 
(Diptee et al., 2007). 
Obviously,   more   research   is  needed   in   order   to 
evaluate the PPA-ELISA in field buffaloes and also to 
determine the correct dose to be used in adult and young 
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